Pfizer Inc (PFE) 28.91 $PFE
Most active New York Stock Exchange-traded stocks
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
ViiV Healthcare's Single-Pill HIV Drug Triumeq Cleared by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 3:30PM CDT
GlaxoSmithKline (GSK) announced that Triumeq has been cleared by the FDA for the treatment of HIV-1 infection.
Dow Today: Pfizer (PFE) Higher
at The Street - Mon Aug 25, 1:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE
FE), which is sporting a two-cent gain to $28.94.
Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal
at The Street - Mon Aug 25, 12:24PM CDT
TheStreet's Jim Cramer explains why the InterMune (ITMN) deal means big pharma is thinking big.
Early Glance: Pharmaceuticals companies
AP - Mon Aug 25, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
PR Newswire - Mon Aug 25, 8:00AM CDT
On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
ViiV Healthcare receives FDA approval for Triumeq(R) (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
PR Newswire Europe - Fri Aug 22, 3:01PM CDT
ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq((R)) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
CNW Group - Fri Aug 22, 2:46PM CDT
ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Pfizer (PFE) Crosses Pivot Point Resistance at $28.96
Comtex SmarTrend(R) - Fri Aug 22, 12:58PM CDT
Shares of Pfizer (NYSE FE) have bullishly opened above the pivot of $28.85 today and have reached the first resistance level of $28.96. Should the shares continue to rise, the resistance pivots of $29.10 and $29.35 will be of interest.
Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry
M2 - Fri Aug 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g8ls35/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering. The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018. There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease. Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options. The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: - Alkylating Antineoplastic Agents - Antibiotic Antineoplastic Agents - Antineoplastics Vinca Alkaloid Agents - Podophyllotoxin Derivative Antineoplastic Agents - Antimetabolite Antineoplastic Agents - Anthracycline Antineoplastic Agents - Antimicrotubular Antineoplastics - Corticosteroids Key Vendors - Bristol Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Merck & Co. Inc. - Pfizer Inc. Other Prominent Vendors - 4SC AG - Actinium Pharmaceuticals Inc. - Aeterna Zentaris Inc. - Affimed Therapeutics AG - Hospira Inc. - Incyte Corp. - Novartis AG - Philogen S.p.A. - Seattle Genetics Inc. - Sigma-Tau Pharmaceuticals Inc. - Stemline Therapeutics Inc. - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/g8...l_hodgkins
Intel, Home Depot, Microsoft Lead DJIA During Earnings Season
at The Street - Fri Aug 22, 8:00AM CDT
On Thursday, Home Depot became the last Dow component to report quarterly results. Here's how the 30 stocks in the DJIA fared during earnings season.
Most active New York Stock Exchange-traded stocks
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
ViiV Healthcare's Single-Pill HIV Drug Triumeq Cleared by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 3:30PM CDT
GlaxoSmithKline (GSK) announced that Triumeq has been cleared by the FDA for the treatment of HIV-1 infection.
Dow Today: Pfizer (PFE) Higher
at The Street - Mon Aug 25, 1:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE
FE), which is sporting a two-cent gain to $28.94. Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal
at The Street - Mon Aug 25, 12:24PM CDT
TheStreet's Jim Cramer explains why the InterMune (ITMN) deal means big pharma is thinking big.
Early Glance: Pharmaceuticals companies
AP - Mon Aug 25, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
PR Newswire - Mon Aug 25, 8:00AM CDT
On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
ViiV Healthcare receives FDA approval for Triumeq(R) (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
PR Newswire Europe - Fri Aug 22, 3:01PM CDT
ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq((R)) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
CNW Group - Fri Aug 22, 2:46PM CDT
ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Pfizer (PFE) Crosses Pivot Point Resistance at $28.96
Comtex SmarTrend(R) - Fri Aug 22, 12:58PM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $28.85 today and have reached the first resistance level of $28.96. Should the shares continue to rise, the resistance pivots of $29.10 and $29.35 will be of interest. Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry
M2 - Fri Aug 22, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g8ls35/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering. The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018. There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease. Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options. The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: - Alkylating Antineoplastic Agents - Antibiotic Antineoplastic Agents - Antineoplastics Vinca Alkaloid Agents - Podophyllotoxin Derivative Antineoplastic Agents - Antimetabolite Antineoplastic Agents - Anthracycline Antineoplastic Agents - Antimicrotubular Antineoplastics - Corticosteroids Key Vendors - Bristol Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Merck & Co. Inc. - Pfizer Inc. Other Prominent Vendors - 4SC AG - Actinium Pharmaceuticals Inc. - Aeterna Zentaris Inc. - Affimed Therapeutics AG - Hospira Inc. - Incyte Corp. - Novartis AG - Philogen S.p.A. - Seattle Genetics Inc. - Sigma-Tau Pharmaceuticals Inc. - Stemline Therapeutics Inc. - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/g8...l_hodgkins
Intel, Home Depot, Microsoft Lead DJIA During Earnings Season
at The Street - Fri Aug 22, 8:00AM CDT
On Thursday, Home Depot became the last Dow component to report quarterly results. Here's how the 30 stocks in the DJIA fared during earnings season.
